World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
75
Citations
25594
World Ranking
19030
National Ranking
9487

Gary L. Davis publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gary L. Davis sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 255 publications — 9th percentile

9% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gary L. Davis D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gary L. Davis sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 75 D-Index — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gary L. Davis is affiliated with the University of Florida in the United States. Their research primarily focuses on the field of Medicine with particular attention to various subfields including Infectious Diseases, Epidemiology, Modeling and Simulation, Pathology and Forensic Medicine, and Pulmonary and Respiratory Medicine.

The scientist's work covers multiple topics, such as:

  • Clostridium difficile and Clostridium perfringens research
  • Microscopic Colitis
  • Viral gastroenteritis research and epidemiology
  • COVID-19 epidemiological studies
  • Lymphoma Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Esophageal Cancer Research and Treatment

Notable recent papers authored or coauthored by Gary L. Davis include:

  • "European survey on the current surveillance practices, management guidelines, treatment pathways and heterogeneity of testing of Clostridioides difficile, 2018-2019: results from The Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI)", 2022, Journal of Hospital Infection
  • "AI, IOT, AND AIOT: DEFINITIONS AND IMPACTS ON THE ARTIFICIAL INTELLIGENCE CURRICULUM", 2020, Issues in Information Systems
  • "ACCURACY OF SIMPLE FORECASTING METHODS IN PREDICTING COVID-19 INCIDENCE IN NEW YORK CITY", 2020, Issues in Information Systems
  • "418 | CIRCULATING TUMOR DNA ASSESSMENT IN PATIENTS WITH EARLY-STAGE CLASSICAL HODGKIN LYMPHOMA TREATED WITH COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB", 2025, Hematological Oncology
  • "Feasibility of Holmium Laser Enucleation of the Prostate (HoLEP) After Prior Prostate intervention for benign prostatic hyperplasia (BPH)", 2025, SSRN Electronic Journal

Frequent coauthors in Gary L. Davis's research include:

  • John Stewart
  • Robert Morris
  • Diane Igoche
  • Peyman Mokhtarzadehazar
  • B. Scott Ferguson

Gary L. Davis has contributed to publications in several venues with multiple contributions to Issues in Information Systems, and additional works published in Journal of Hospital Infection, Hematological Oncology, SSRN Electronic Journal, and Urology.

Best Publications

  • Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

    Davis Gl;Balart La;Schiff Er;Lindsay K

  • Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C

    Gary L. Davis;Rafael Esteban-Mur;Vinod Rustgi;John Hoefs

  • Significance of serum hepatitis C virus RNA levels in chronic hepatitis C

    J.Y.N Lau;G.L Davis;J Kniffen;K.-P Qian

  • A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B

    Robert P. Perrillo;Eugene R. Schiff;Gary L. Davis;Henry C. Bodenheimer

  • Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression

    Gary L Davis;Miriam J Alter;Hashem El-Serag;Thierry Poynard

  • Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C

    Gary L. Davis;John B. Wong;John G. McHutchison;Michael P. Manns

  • Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

    H C Bodenheimer;K L Lindsay;G L Davis;J H Lewis

  • Pathological diagnosis of chronic hepatitis C: A multicenter comparative study with chronic hepatitis B

    Jay H. Lefkowitch;Eugene R. Schiff;Gary L. Davis;Robert P. Perrillo

  • Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders ☆ ☆☆

    David R. Nelson;Gregory Y. Lauwers;Johnson Y.N. Lau;Gary L. Davis

  • Factors predictive of a beneficial response to therapy of hepatitis C

    G. L. Davis;J. Y. N. Lau

  • Estimates of the Cost-Effectiveness of a Single Course of Interferon-α2b in Patients with Histologically Mild Chronic Hepatitis C

    W G Bennett;Y Inoue;J R Beck;J B Wong

  • Health‐related quality of life in chronic hepatitis C: Impact of disease and treatment response

    John E. Ware;Martha S. Bayliss;Martha S. Bayliss;Michael Mannocchia;Gary L. Davis

  • Impact of Interferon Alfa-2b and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C

    Thierry Poynard;John McHutchison;Gary L. Davis;Rafael Esteban-Mur

  • The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C.

    D. R. Nelson;C. G. Marousis;G. L. Davis;C. M. Rice

  • Spontaneous reactivation of chronic hepatitis B virus infection.

    Gary L. Davis;Jay H. Hoofnagle;Jeanne G. Waggoner

  • Hepatic adenoma and focal nodular hyperplasia: Clinical, pathologic, and radiologic features

    P. Kerlin;G.L. Davis;D.B. McGill;L.H. Weiland

  • Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect.

    David R. Nelson;Zhengkun Tu;Consuelo Soldevila-Pico;Manal Abdelmalek

  • Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients.

    Gary L. Davis;Johnson Y.-N. Lau;Mickie S. Urdea;Paul D. Neuwald

  • Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease

    Kanthi Yalamanchili;Kanthi Yalamanchili;Sherif Saadeh;Göran B. Klintmalm;Linda W. Jennings

  • Activation of Tumor Necrosis Factor-α System in Chronic Hepatitis C Virus Infection

    David R. Nelson;Herbert L. Lim;Constantine G. Marousis;Jane W. S. Fang

Frequent Co-Authors

Johnson Y.N. Lau
Johnson Y.N. Lau Hong Kong Baptist University
Masashi Mizokami
Masashi Mizokami National Center For Global Health and Medicine
Joseph Lau
Joseph Lau Chinese University of Hong Kong
David R. Nelson
David R. Nelson University of Tennessee Health Science Center
Robert G. Gish
Robert G. Gish University of Nevada Reno
John B. Wong
John B. Wong Tufts University
Jules L. Dienstag
Jules L. Dienstag Harvard University
John G. McHutchison
John G. McHutchison Duke University
Mickey S. Urdea
Mickey S. Urdea Halteres Associates
Eugene R. Schiff
Eugene R. Schiff University of Miami

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a traditional medical degree in the USA is just one of many ways to enter the healthcare field. Many students and professionals are now considering flexible online programs that lead to diverse career pathways. For those interested in healthcare management, a health administration degree offers skills to work in hospitals, clinics, or health organizations without direct patient care.

If you want to advance further in healthcare leadership, exploring the mha degree cost may help you find affordable options for your master's. Clinical professionals seeking to elevate their healthcare practice might consider pursuing dnp online programs cheap, which prepare graduates for the highest levels of nursing practice.

Those interested in pharmacy can also benefit from flexible, accredited online programs. The 3-year online pharmd can fast-track students to pharmaceutical careers in a cost-effective way. These online options make healthcare careers more accessible, diverse, and aligned with your personal goals.

Best Scientists Citing Gary L. Davis

Trending Scientists

Recently Published Articles